PUBLISHER: The Business Research Company | PRODUCT CODE: 1662573
PUBLISHER: The Business Research Company | PRODUCT CODE: 1662573
Biosurgery involves utilizing live maggots to remove dead tissue, minimize infection risks, and accelerate wound healing. This field encompasses semi-synthetic, synthetic, or natural materials that aid in the recuperation of surgical incisions and tissue regeneration.
Primary biosurgery products include bone-graft substitutes, soft-tissue attachments, hemostatic agents, surgical sealants and adhesives, adhesion barriers, and staple line reinforcement. Bone graft substitutes are materials, natural or synthetic, used to fill bone voids and facilitate bone mending. These products stem from natural or biological sources as well as synthetic origins. They find application in orthopedic, general, neurological, cardiovascular, gynecological surgeries, and others, catering to end-users such as hospitals, clinics, and similar facilities.
The biosurgery market research report is one of a series of new reports from The Business Research Company that provides biosurgery market statistics, including biosurgery industry global market size, regional shares, competitors with a biosurgery market share, detailed biosurgery market segments, market trends and opportunities, and any further data you may need to thrive in the biosurgery industry. This biosurgery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The biosurgery market size has grown strongly in recent years. It will grow from $15.27 billion in 2024 to $16.49 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to increasing surgical procedures, rise in chronic diseases, growing geriatric population, shift towards biodegradable product, regulatory changes, and approvals.
The biosurgery market size is expected to see strong growth in the next few years. It will grow to $22.98 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to advancements in tissue engineering, rise in minimally invasive procedures, focus on regenerative medicine, shift towards biologics, aging population needs. Major trends in the forecast period include growth in minimally invasive procedures, rise in cosmetic and plastic surgeries, focus on stem cell therapies, advancements in wound care, development of biodegradable products.
The biosurgery market is poised for growth, primarily driven by the increasing prevalence of chronic diseases. Chronic diseases, lasting for a year or longer and requiring ongoing medical care, significantly impact individuals' health, restricting daily activities. In the U.S., chronic diseases such as diabetes, cancer, and heart disease are leading causes of death and disability. Biosurgery plays a crucial role in managing chronic wounds by eliminating dead tissue, reducing infection risk, and expediting the healing process. For example, in March 2022, the Australian Bureau of Statistics reported that 78.6% of Australians suffered from at least one chronic illness, affecting over half of the population. The rise in chronic diseases is a key factor propelling the growth of the biosurgery market.
A significant factor contributing to the growth of the biosurgery market is the increase in the number of accidents. Accidents, unforeseen events causing harm or injury, occur in various settings such as daily life, workplaces, transportation, and sports. Biosurgery is utilized in accident scenarios to mitigate blood loss, facilitate effective coagulation, and promote wound healing in traumatic situations, injuries, or surgical operations. In 2022, the Department of Infrastructure, Transport, Regional Development, and Communications in Australia reported 1,194 fatal traffic accidents, indicating a 5.8% increase over the previous year. The growth in accident numbers is driving the adoption of biosurgery for effective wound management.
Major companies in the biosurgery market are utilizing technological advancements, particularly in advanced wound care technology, to improve healing outcomes, reduce infection rates, and enhance patient recovery times through innovative products and techniques. Advanced wound care technology includes cutting-edge methods and products aimed at promoting wound healing, preventing infections, and improving overall patient outcomes. For example, in September 2024, Health Care at Home India Pvt Ltd, an India-based manufacturer of medical products, launched the WOW (Warriors of Woundcare) Nurses initiative. This program aims to proactively prevent and treat bedsores, which are common complications for patients with limited mobility. Bedsores can significantly impede recovery, prolong hospital stays, and increase the risk of infections.
Prominent companies in the biosurgery market are increasingly adopting a strategic partnership approach to enhance their capabilities and expand their market presence. Strategic partnerships involve leveraging the strengths and resources of collaborating companies for mutual benefits and success. In a notable example, Biocomposites Ltd., a UK-based manufacturing company specializing in calcium compound solutions for bone and soft tissue regeneration and repair, entered into an agreement with Zimmer Biomet Holdings Inc. in March 2022. Under this agreement, Biocomposites exclusively sells genex Bone Graft Substitute in the US orthopedic market. Genex Bone Graft Substitute is a biphasic composite with excellent purity, precisely developed to balance osteoconductive scaffold toughness and persistence in the body, facilitating optimal bone architecture rebuilding. The partnership includes enhancements for the US market, incorporating a new closed-mixing method to save preparation time and extend working time. It also offers a broader range of delivery options, enabling surgeons to inject, shape, or prepare beads according to their preferred approach.
In June 2022, GTCR LLC, a US-based private equity firm, acquired Barron Precision Instruments, LLC, for an undisclosed amount. This acquisition is part of GTCR LLC's strategy to drive growth and enhance operations within Barron Precision Instruments. Barron Precision Instruments, LLC, is a US-based manufacturer known for producing high-quality medical instruments.
Major companies operating in the biosurgery market include Baxter International Inc., B. Braun SE, Becton, Dickinson and Company, Hemostasis LLC, Integra LifeSciences Corporation, Johnson & Johnson Services Inc., CryoLife Inc., CSL Limited, Pfizer Inc., Zimmer Biomet Holdings Inc., Kuros Biosciences AG, Orthofix Medical Inc., Smiths & Nephew plc, Medtronic plc, Stryker Corp., Betatech Medical, Tissue Regenix Group plc, Aroa Biosurgery Ltd., Anika Therapeutics Inc., Arthrex Inc., B Braun Surgical SA, Biom'Up SA, Boston Scientific Corporation, Coloplast Corp., Cook Medical Inc., Endo International plc, Genzyme Corporation, Takeda Pharmaceutical Company Limited, Cerus Corporation
North America was the largest region in the biosurgery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the biosurgery market report during the forecast period. The regions covered in the biosurgery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the biosurgery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The biosurgery market consists of revenues earned by entities by providing biosurgery services such as maggot therapy, transplantation, and autologous chondrocyte implantation. The market value includes the value of related goods sold by the service provider or included within the service offering. The biosurgery market also includes sales of absorbable hemostats and surgical sealants which are used in providing biosurgery services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Biosurgery Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on biosurgery market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for biosurgery ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biosurgery market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Subsegments;